文献速递介入腹部USDSA

可吸收支架治疗良性胆管狭窄:西班牙前瞻性登记研究长期随访结果

Absorbable stents for treatment of benign biliary strictures: long-term follow-up in the prospective Spanish registry.
PubMed 文献 · Eur Radiol · 2020-03-27

西班牙11家三级医院前瞻性纳入159例以术后良性胆管狭窄为主的患者,植入可吸收聚二氧环己酮胆道支架并随访平均45.4±15.9个月。即刻技术和临床成功率为100%,支架12、36、60个月原发通畅率分别为86.7%、79.6%、78.9%,40例(26.6%)发生再狭窄或闭塞,无支架植入相关重大并发症。

要点

  • 可吸收聚二氧环己酮胆道支架植入后即刻技术和临床成功率均为100%。
  • 支架12、36、60个月原发通畅率分别为86.7%、79.6%、78.9%。
  • 40例(26.6%)发生胆道再狭窄或闭塞,其中18例(12%)置入第二枚支架、22例(14.6%)手术修复。

关键影像表现/征象

  • 随访内容包括症状、生化指标和超声图像,于1、6、12个月及之后每年复查至60个月。
  • 所有患者支架置入后临床症状和生化指标均改善,黄疸、瘙痒、发热在支架置入后数天内改善。

诊断标准与关键数值

  • 即刻技术和临床成功率均为100%。
  • 支架原发平均通畅率12个月为86.7%、36个月为79.6%、60个月为78.9%(95%CI)。
  • 40例(26.6%)发生胆道再狭窄和闭塞,其中18例(12%)接受第二枚支架治疗、22例(14.6%)对复发性狭窄行手术修复。
  • 无与支架植入相关的重大并发症。

临床应用与阅片要点

  • 原文结论认为,可吸收聚二氧环己酮胆道支架植入对球囊扩张或其他胆道介入难治的良性胆管狭窄安全有效。
  • 原文要点指出,经皮植入可生物降解假体治疗术后良性胆管狭窄是安全有效的操作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Benign strictures of the bile duct may be difficult to treat endoscopically due to altered bowel anatomy. Furthermore, recurrence of stenosis and symptoms remains high. The aim of the Spanish Prospective Registry BiELLA study was to investigate the safety and efficacy of absorbable stents in the treatment of benign biliary strictures and their outcomes on the medium and long-term follow-up.

METHODS: A prospective, multicenter, observational, non-randomized study (the BiELLA study) was conducted from January 2014 to September 2018. One hundred fifty-nine patients with benign biliary strictures, mostly postsurgical, were enrolled for implantation of absorbable biliary stents in the 11 participating Spanish tertiary hospitals. The average patient follow-up was 45.4 ± 15.9 months (range, 12-60 months). The follow-up data included symptoms, biochemical parameters, and ultrasound images at 1, 6, and 12 months and then yearly for up to 60 months.

RESULTS: The immediate technical and clinical success rates were 100%. In all patients, stent placement resulted in improvement of clinical symptoms and biochemical parameters. The primary mean patency for stent was 86.7, 79.6, and 78.9% at 12, 36, and 60 months, respectively (95% CI). Biliary restenosis and occlusion occurred in 40 (26.6%) patients. Of the 40 patients, 18 (12%) patients were treated with a second stent and 22 (14.6%) patients had operative repair of the recurrent strictures. There were no major complications associated with stent implantation.

CONCLUSIONS: Implantation of an absorbable polydioxanone biliary stent is safe and effective for treatment of benign biliary strictures refractory to balloon dilatation or other biliary intervention.

KEY POINTS: • Percutaneous implantation of biodegradable prostheses for the treatment of benign postsurgical biliary strictures is a safe and effective procedure. • More than 75% of the patients presented patency of the stented biliary tree at 5 years follow-up. • Absorbable stents improved clinical symptoms and signs (jaundice, itching, fever), and laboratory parameters in a few days after stent placement.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. De Gregorio MA, Criado E, Guirola JA, et al. Absorbable stents for treatment of benign biliary strictures: long-term follow-up in the prospective Spanish registry. Eur Radiol. 2020. PMID: 32221684. doi:10.1007/s00330-020-06797-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。